Patent · US Active

Pyrazine compounds and uses thereof

US10898481B2 · kind B2 · utility

1Cited by

0References

6Claims

0Family size

Inventors

Changhe Qi · Shanghai, CN
Honchung Tsui · Shanghai, CN
Qingbei Zeng · Shanghai, CN
Zhenfan Yang · Shanghai, CN
Xiaolin Zhang · Singapore, SG

Key dates

Filing date	Jun 24, 2020
Grant date	Jan 26, 2021
Priority date	—
Expiry date	Jun 24, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D519/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure novel pyrazine compounds targeting adenosine receptors (especially A1 and A2, particularly A2a). The present disclosure also relates to pharmaceutical compositions comprising one or more of the compounds as an active ingredient, and use of the compounds in the treatment of adenosine receptor (AR) associated diseases, for example cancer such as NSCLC, RCC, prostate cancer, and breast cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.